| * The Ordinary Shares reported above include 693,000 Ordinary Shares owned directly by Beijing Sangel Fang Sheng Venture Capital (Limited Partnership) (“Beijing Sangel”), 175,000 Ordinary Shares owned directly by Shenzhen Sangel Jing Rui Venture Capital (Limited Partnership) (“Shenzhen Sangel Jing”), 124,066 Ordinary Shares owned directly by Shenzhen Sangel Sino-Euro Venture Capital (Limited Partnership) (“Shenzhen Sangel Sino”), and 74,756 Ordinary Shares owned directly by Sangel Star Biomedical Fund LP (“Sangel Star Biomedical”). The Reporting Person is the sole general partner of each of Beijing Sangel, Shenzhen Sangel Jing, and Shenzhen Sangel Sino, and the Reporting Person is an affiliate of Sangel Star Biomedical and, as such, has the ability to direct the management of the business of each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical, including the power to direct decisions regarding the vote and disposition of securities held by each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical; therefore, the Reporting Person may be deemed to have indirect beneficial ownership of the Ordinary Shares held by each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical. The Ordinary Shares reported above include 187,800 Ordinary Shares owned directly by Beijing Huarong Sangel Venture Capital (Limited Partnership) (previously named Beijing Sangel Venture Capital (Limited Partnership)) (“ Beijing Huarong Sangel”). The Reporting Person and Huarong Tianze Investments Limited (“ Huarong Tianze”) are the general partners of Beijing Huarong Sangel and share the ability to direct the management of the business of Beijing Huarong Sangel, including the power to direct decisions regarding the vote and disposition of securities held Beijing Huarong Sangel; therefore, the Reporting Person and Huarong Tianze may each be deemed to have indirect beneficial ownership of the Ordinary Shares held by Beijing Huarong Sangel. The percentages used in this Schedule 13G/A are calculated based upon the Issuer’s 39,142,253 issued and outstanding Ordinary Shares as of September 30, 2021, as reported by the Issuer in its press release, attached as Exhibit 99.1 to its Form 6-K filed with the U.S. Securities and Exchange Commission on December 30, 2021. |